http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2537328-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fd8da0a02c7c4256f144f2c47dc0bab8 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-745 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-37 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-11 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-745 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-36 |
| filingDate | 2008-04-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2015-06-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_50de293818e1aad88e46b545eb45b0f8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8349f04f310e11c6010d53b3be731861 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5f40b5b6c3bd347a2d5f5d0c407bf6d5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c8b3e576da41518c6cac4cae13c87dc9 |
| publicationDate | 2015-06-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2537328-T3 |
| titleOfInvention | Modified factor VII polypeptides and uses thereof |
| abstract | A modified Factor VII (FVII) polypeptide, comprising: a heterologous Gla domain, or a sufficient part thereof to effect phospholipid binding, whereby the modified FVII polypeptide shows increased affinity or phospholipid binding compared to a polypeptide of unmodified FVII that does not contain the heterologous Gla domain, where: the sufficient part contains 30 or more contiguous amino acids of the heterologous Gla domain; and the heterologous Gla domain is selected from a Gla domain in factor IX (FIX), Factor X (FX), prothrombin, protein C, protein S, osteocalcin, growth arrest specific protein 6 (Gas6) and protein Z; and one or more additional amino acid modifications that increase resistance to antithrombin III (AT-III), increase affinity for tissue factor (FT), increase intrinsic activity, increase catalytic or coagulant activity dependent on FT, increase activity coagulant, alter the conformation of the polypeptide to alter the zymogenicity, increase the catalytic or coagulant activity shifting the balance between highly active and less active FVIIa conformations in favor of highly active conformations, increase protease resistance, reduce glycosylation, increase glycosylation glycosylation, reduce immunogenicity, increase stability and / or facilitate the bonding of chemical groups. |
| priorityDate | 2007-04-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 687.